Stay updated on Gantenerumab in Prodromal Alzheimer's: Clinical Trial
Sign up to get notified when there's something new on the Gantenerumab in Prodromal Alzheimer's: Clinical Trial page.

Latest updates to the Gantenerumab in Prodromal Alzheimer's: Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page now displays the completed gantenerumab study record for prodromal Alzheimer’s disease, including its open-label extension, outcome measures, participant criteria, and study documents.SummaryDifference100%

- Check18 days agoChange DetectedThe footer’s displayed site revision changes from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check25 days agoChange DetectedA notice appears above the study page announcing NIH’s transition from “Artificial Intelligence” to “Super Intelligence” terminology and linking to transition updates and FAQs.SummaryDifference1%

- Check32 days agoChange DetectedThe footer’s site revision identifier changes from v3.7.1 to v3.7.2; the 403 error page otherwise remains unchanged.SummaryDifference0.2%

- Check39 days agoChange DetectedThe ClinicalTrials.gov site footer revision changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check60 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study record content, replaced by a minimal error view with a Home link.SummaryDifference18%

Stay in the know with updates to Gantenerumab in Prodromal Alzheimer's: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Gantenerumab in Prodromal Alzheimer's: Clinical Trial page.